AEQUUS PHARMACEUTICALS INC (AQS.CA)

Aequus Reports Second Quarter 2023 Financial Highlights and General Update

VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a...

Aequus Announces Zimed PF Now Available in Canada

VANCOUVER, British Columbia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), ) (“Aequus” or the “Company”), a...

Aequus Announces Zimed PF Website Launch

VANCOUVER, British Columbia, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), ) (“Aequus” or the “Company”), a...

Aequus Pharmaceutical Canada Announces a Pause in Sales of Evolve Intensive Eyedrops and Gel in Canada

VANCOUVER, British Columbia, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), ) (“Aequus” or the “Company”), a...

Aequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%)

VANCOUVER, British Columbia, July 06, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”),...

Aequus Provides General Update and First Quarter 2023 Financial Highlights

VANCOUVER, British Columbia, May 30, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a...

Aequus Provides General Update and Fiscal 2022 Financial Results

VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a...

Aequus Grants Stock Options

VANCOUVER, British Columbia, April 19, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”),...

Aequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%) and Board Update

VANCOUVER, British Columbia, April 05, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”),...

Aequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%)

VANCOUVER, British Columbia, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), is...

Aequus Reports Third Quarter 2022 Financial Highlights

VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a...

Aequus Reports Second Quarter 2022 Financial Highlights and General Update

VANCOUVER, British Columbia, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a...

Press Release for Early Warning Report Regarding Aequus Pharmaceuticals Inc.

VANCOUVER, British Columbia, July 23, 2022 (GLOBE NEWSWIRE) -- Doug Janzen, of 2820 – 200 Granville St., Vancouver, BC, V6C 1S4, today announced that on...

Aequus Resumes Trading on TSX Venture Exchange

VANCOUVER, British Columbia, July 13, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) announces that further to our news...

Aequus Signs Exclusive Distribution Agreement with SCOPE Ophthalmics for Canadian Distribution Rights of Dry Eye Products

VANCOUVER, British Columbia, July 06, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is...

Aequus Provides General Update and Reports Record 2021 Financial Results

Also reports Financial Results for the 3 months ended March 31, 2022 VANCOUVER, British Columbia, July 01, 2022 (GLOBE NEWSWIRE) -- Aequus...

Aequus Provides Update on Delay in Filing Annual Financial Statements

VANCOUVER, British Columbia, June 13, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”)...

Aequus Provides Update on Delay in Filing Annual Financial Statements

VANCOUVER, British Columbia, May 27, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”)...

Aequus Provides Update on Delay in Filing Annual Financial Statements

VANCOUVER, British Columbia, May 06, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”)...

Aequus Announces Delay in Filing Annual Financial Statements

VANCOUVER, British Columbia, May 02, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”)...

Aequus Announces Short Term Loan

VANCOUVER, British Columbia, May 02, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”)...

Aequus Announces Director Resignation

VANCOUVER, British Columbia, April 22, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), a specialty pharmaceutical...

Aequus Announces Canadian Filing of NDS for Preservative-Free Glaucoma Medication

Health Canada Submission of Preservative-Free Prescription ‘Zimed PF’ Accepted for Screening VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE)...

Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021

LOS ANGELES, CA / ACCESSWIRE / December 6, 2021 / The SNN Network Canada Virtual Event will take place on December 7-9, 2021, where 70 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience. The SNN Network Canada Virtual Event begins on Tuesday, December 7, 2021 with the "MicroCap Investing Workshop" starting at 8:00am EST and featuring well-known financial influencers,

Aequus Reports Third Quarter 2021 Financial Highlights

Second Largest Revenue Quarter in Company History and New Evolve Product Sales Double...

Aequus Reports Second Quarter 2021 Financial Highlights

Second Highest Quarterly Revenues in Company History

Aequus Strengthens Clinical Experience in Stargardt Disease with Pediatric Ophthalmology Expertise

Aequus and reVision to Collaborate on Stargardt Disease Program

Aequus Gains Option for North American Commercial Rights

Aequus and reVision to Collaborate on Stargardt Disease Program

Aequus Gains Option for North American Commercial Rights

Aequus Provides Commercial Update

Aequus Provides General Update and First Quarter 2021 Financial Highlights

Aequus Provides General Update and Reports Record 2020 Financial Results

Aequus to Present at the 2021 Bloom Burton & Co. Healthcare Investor Conference

Aequus Launches Evolve Eyedrops to Eye Care Professionals in Canada

Aequus Pharma 2021 Outlook and Holiday Wishes

Aequus Provides Third Quarter 2020 Financial Highlights

Record Third Quarter Revenues – 67% Increase Over Same Period Last Year

Aequus Announces Anne Stevens’ Leadership Change

Aequus Receives Approval for New ‘Evolve - Daily Intensive’ Lubricating Eye Drops in Canada

Aequus Announces Approval of Fourth Revenue Generating Product

Aequus Receives Approval for New ‘Evolve - Intensive Gel’ Lubricating Eye Drops in Canada

Aequus Announces Approval of Third Revenue Generating Product

Aequus Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada